Aaron Tallent

Community oncology practices can point to advantages such as care closer to home, greater affordability, and a more personalized experience. However, demonstrating the quality of that care with data can be more challenging.

Learn how community oncology practices are successfully implementing bundled payments, improving care coordination, and reducing costs for cancer patients.

Explore how oncology partnerships are transforming utilization management through innovative approaches that improve patient care and streamline processes.

Explore the phase 3 mRNA vaccine results and their implications for melanoma treatment and prevention.

Study finds HRR mutations in metastatic prostate cancer may lead to worse overall survival and progression-free survival.

Daraxorasib (Rasonque) is approved for metastatic pancreatic ductal adenocarcinoma, offering new treatment options for patients.

FDA approves zanidatamab for HER2-positive gastroesophageal cancer in frontline settings, offering a new treatment option for patients.

FDA approves lutetium Lu 177 vipivotide tetraxetan plus ARPI for metastatic hormone-sensitive prostate cancer, expanding treatment options.

Learn how talazoparib and enzalutamide improve progression-free survival in men with metastatic castration-sensitive prostate cancer.

FDA panel recommends approval for Vusolimogene oderparepvec to treat advanced melanoma, marking a significant advancement in cancer therapy.

The LungTIME-C01 study linking immunochemotherapy timing to survival in lung cancer was retracted. Learn what this means for treatment scheduling.

The American Society of Clinical Oncology issued its first guidelines for the use of blood-based ctDNA testing in diagnosis, therapy selection, surveillance, and prognosis in solid tumors and lymphoma. Among the key recommendations is that ctDNA should be used as a complementary tool versus a replacement for standard testing.

AYA cancer patients with sarcoma may not know resources, including palliative care, are available, and may resist them when offered.

An analysis of more than 200 hospitals found a very high mortality rate in non–COVID-19 ICU patients with invasive candidiasis.

In a single-arm, 2-stage study, tofacitinib reduced irAE rates, suggesting its potential as a bridging therapy to resolve irAEs and enable resumption of ICI treatment (Abstract 81). Randomized clinical trials involving multiple study centers and comparisons with standard glucocorticoid therapy are needed to further explore tofacitinib for addressing irAEs.

The latest findings from ASCO 2026 show how new treatment paradigms are shifting in early-stage breast cancer.

Adjuvant selpercatinib improves event-free survival in early-stage RET-positive NSCLC, potentially changing post-surgery treatment.

Ramelteon does not reduce postoperative delirium in older patients after major cancer surgery, phase 3 trial shows.

The PROTEUS trial shows that perioperative androgen receptor pathway inhibitor therapy improves metastasis-free survival in high-risk localized prostate cancer.

DISC-0974 produces durable hematologic responses in the ongoing phase 2 RALLY-MF trial in patients with myelofibrosis and anemia, indicating potential for benefit in a group of patients for whom no U.S. Food and Drug Administration–approved anemia treatment currently exists, despite the prevalence of inflammation and anemia in this population (Abstract 6501).